← SynDRA
Y-39983
SynDRA canonical compound SYN0020196 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | ROCK2 |
|---|
| Mechanism of action | Rho associated kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- Rho associated kinase inhibitor
- ROCK2 INHIBITOR
- Rho-associated protein kinase inhibitor
- ROCK1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PAK2
- PDXK
- PDGFRB
- PCYT1A
- PASK
- PAK6
- PAK4
- PAICS
- PFKP
- OPA1
- OLA1
- NUAK2
- NTRK1
- NQO2
- NLK
- PEBP1
- PHKG2
- NEK3
- PLK4
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PRKAA1
- PLK1
- PIM1
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- PIP4K2A
- NEK9
- NEK2
- MAP3K6
- MAPK14
- MAPKAPK2
- MAPK9
Cross-references
Synonyms
- RKI-983
- SNJ-1656
- ROCK inhibitors, Mitsubishi Tanabe Pharma/Senju/Novartis
- Rho-associated protein kinase inhibitors, Mitsubishi Tanabe Pharma/Senju/Novartis
- Y-33075
- Y-39983 free base
- RefChem:195576
- DTXCID2096209
- Y33075
- UNII-00ALI1GAY2
- SCHEMBL226556
- orb1708189
- SCHEMBL29431274
- CHEBI:91412
- EX-A5296A
- ZHA43358
- BDBM50319005
- NSC800973
- AKOS030526699
- CS-0097
- NSC-800973
- NCGC00346944-01
- NCGC00346944-02
- DA-68755
- HY-10067
- MS-23981
- F82407
- T13384
- BRD-K56751279-001-01-8
- BRD-K56751279-300-01-4
- y-33075
- Y-33075 (hydrochloride)
- HY-10068
- AKOS030231070
- Y 39983HCl?
- RefChem:195577
- UNII-3304VH0J6B
- CS-0002430
- Y-39983 hydrochloride
Look up Y-39983 in the interactive SynDRA portal →